W. Jan



Class IIb

Benefit ≥ Risk
Additional studies with broad
objectives needed; additional
registry data would be helpful
Procedure/Treatment

■ Recommendation's usefulness/efficacy less well established

MAY BE CONSIDERED

- Greater conflicting evidence from multiple randomized trials or meta-analyses
- Recommendation's usefulness/efficacy less well established
- Greater conflicting evidence from single randomized trial or nonrandomized studies
- Recommendation's usefulness/efficacy less well established
- Only diverging expert opinion, case studies, or standard-of-care

Class III Risk ≥ Benefit No additional studies needed

Procedure/Treatment should NOT be performed/administered SINCE IT IS NOT HELP-FUL AND MAY BE HARMFUL

- Recommendation that procedure or treatment is not useful/effective and may be harmful
- Sufficient evidence from multiple randomized trials or meta-analyses
- Recommendation that procedure or treatment is not useful/effective and may be harmful
- Limited evidence from single randomized trial or nonrandomized studies
- Recommendation that procedure or treatment is not useful/effective and may be harmful
- Only expert opinion, case studies, or standard-of-care

- A mm , L_L , E, B C , m , . . .
- to the transfer of the first transfer of the

m /m, m /m,

I. La E a a ... a Mara

R . _ a a . a . . . La a T.a

Ca. I (\downarrow , \downarrow ,

(Level of Evidence: C)

B. Ea R. S. a a

R . _ _ _ _ _ a a . _ _ _ _ ,

> $\frac{z_{-1}z_{-1}}{z_{-1}z_{-1}} \frac{z_{-1}z_{-1}}{z_{-1}z_{-1}} \frac{z_$

, $\xi_1+\cdots \xi \xi_{N}(\xi)+\zeta_{N}(\xi)+\zeta_{N}(\xi)+\zeta_{N}(\xi)$

Evidence: C)

> المناور و مراه و المال المال والمنظم و المالي (Level of Evidence: B) - 11 to 12 t $_{1}$, $_{2}$, $_{3}$ $_{4}$ $_{5}$ $_{1}$ $_{4}$ $_{5}$ $_{5}$ $_{7}$ $_{1}$ $_{1}$ $_{2}$ $_{3}$ $_{4}$ $_{5}$ $_{1}$ $_{1}$ $_{5}$ $_{7}$ $_{1}$ $_{1}$ $_{2}$ $_{3}$ $_{4}$ $_{1}$ $_{1}$ $_{2}$ $_{3}$ $_{4}$ $_{1}$ $_{2}$ $_{3}$ $_{4}$ $_{5}$ $_{1}$ $_{1}$ $_{2}$ $_{3}$ $_{4}$ $_{1}$ $_{2}$ $_{3}$ $_{4}$ $_{4}$ $_{5}$ $_{1}$ $_{5}$ $_{7}$ $_{1}$ $_{1}$ $_{2}$ $_{3}$ $_{4}$ $_{1}$ $_{2}$ $_{3}$ $_{4}$ $_{4}$ $_{5}$ $_{1}$ $_{5}$ $_{7}$ $_{1}$ $_{1}$ $_{2}$ $_{3}$ $_{4}$ $_{4}$ $_{5}$ $_{1}$ $_{4}$ $_{5}$ $_{5}$ $_{7$ $t_{i,j} = t_{i,j} + t_{i$ $\{z_{i,j}, z_{i,j}, z_{i,j},$ 1, 1 (Level of Evidence: C)

(Level of Evidence: C)

II. Ea. H., a Ca.



 $\frac{1}{1}, \frac{1}{1}, \frac$

 $\frac{1}{2} \left(\frac{1}{2} \left(\frac{1}{2} \right) \right) \left(\frac{1}{2} \left(\frac{1}{2} \right) \left(\frac{1}{2} \left(\frac{1}{2} \right) \right) \left(\frac{1}{2} \left(\frac{1}{2} \right) \right) \left(\frac{1}{2} \left(\frac{1}{2} \right) \right) \left(\frac{1}{2} \left(\frac{1}{2} \left(\frac{1}{2} \right) \right) \left(\frac{1}{2} \left(\frac{1}{2} \right) \right) \left(\frac{1}{2} \left(\frac{1}{2} \left(\frac{1}{2} \right) \right) \left$



B. Lia Caradar V., Lia Lara ar S. a.

R . __ _ a a . a,

 $\frac{1}{2}$, $\frac{1}{2}$,



Tab 3.S La La a Ta La Sal :

Preferred Strategy	Patient Characteristics
Invasive	R m
	Б _L , , м . (l)
	N _ m · m
	m m HF
	$H_{i} = \{ \cdot, \cdot, \cdot, \cdot, \cdot \} \qquad m = \{ \cdot, \cdot, \cdot \} \qquad \forall i \in \mathcal{I}_{i} = \{ \cdot, \cdot, \cdot \}$
	H m m s s
	a take take
	PCI , , 6 m
	P. CABG
	H (, IMI, GRACE)
	R . ' L ' . ' . ' (L EF) 40%
Conservative	L , . (, ., IMI, GRACE)
	Ρ, , , , ,
	No The Car

Tab 4. S -T R D a N a a a MI a Pa A W UA/NSTEMI*

Feature	High Risk A ea 1 /e , ea .e . be .e e :
History	A + m - m - m m 48
Character of pain	P · (20 m)

Clinical findings	P. m m, m
ECG	A
Cardiac markers	E , , I, CK-MB (, I. 0.1 . mL)


^{*}E \cdot m \cdot

 $A \qquad \quad m \, AHCPR \, C_{+++} \, P \quad \leftarrow G_{+-+} \quad N \cdot .10, \qquad + A_{++-} : D_{-+-+} \quad \qquad M \quad , \quad m \quad , M \quad 1994.$

C.A. a a A a a a T a

F. 3. A. Pa A. W UA/NSTEMI Mara bartia C. A. A. S. a.


F. 4. Mara A A Da A A A a a Pa A W UA/NSTEMI



* D . . . 5.

- $ASA = \cdots; CABG = \cdots; CAD = \cdots;$

F. S.L., -T. A. L. b T. a a H. a D. a. A UA/NSTEMI



- Fig. 1.11... , μ_{m} , μ_{m} , μ_{m} , μ_{m} , μ_{m} , μ_{m} , μ_{m}
- . Consider A Annother than the contract of the matrix $M_{\rm cont}$, $M_{\rm cont}$

		During
Drug*	Initial Medical Treatment	Patient Received Initial Medical Treatment
Oral antiplatelet therapy		
Α	162 325 m . m · · , "	N 1 m
C , , ,	LD 300 600 m " MD 75 m "	A LD 300 m " M .L
11.11	LD 500 m " MD 250 m " , "	N 1 m
Anticoagulants		
B _L to	0.1 m , 0.25 m	0.5 m , , , , , , , , , , , , , , , ,
D	120 l C ι 12 (m .m m 10,000 l .	I GP II /III
E ,	LD 30 m I , m ., MD=1 m ., C , 12 ; 1 m	L C
F 15	2.5 m, C ,	50 60I , .FH. mm OAI5I _L .

PCI		
Patient Did Not Receive Initial Medical Treatment	After PCI	At Hospital Discharge
162 325 m . m	162 325 m 1 1 m BM m 1 3 m E m 1 , 3 m E m 1 , 4 m 1 , 5 m 1 m 1 m 1 m 1 m 1 m 1 m 1 m 1 m 1 m	162 325 m · · · · 1 m · · · · · · 3 m · · · · · · · · · · ·
LD 300 600 m "	F BM:75 m	F BM:75 m
LD 500 m "	MD 250 m " , "	MD 250 m " , "

Anticoagulants cont'd				
. , , ,	LD 60.	. (m 4,000.)	I GP II /III ,	: .

I GP II /III 1 : 60 70 N ... 1 m

N I GP II /III : : 100 140. . .

MDD 6 J/1

LD 6 J/ 12 1 3 EM7. L / 12 1 / 50.61E B / 12 1 J/ 1 125 96/ /A 6/0 6 -264 11

,

D. R. . S. a . a . . a

R . _ _ a a . a.

 $\frac{1}{1} \frac{1}{1} \frac{1}$

(Level of Evidence: B)



III.C., a R. Aa, a a ...

Ca, I $\frac{1}{1 + \frac{1}{1 + \frac{1$



Ca, III

- of Evidence: C) (u, v) = (v, v) + (v,
- $\frac{1}{2}$, $\frac{1}{2}$,
- $\frac{1}{1}$ (Level of Evidence: C)
- (Level of Evidence: B)


IV.H a D a a a P - H a D a Ca

A.M a R _ _ a

\mathbf{R} , \mathbf{a} \mathbf{a} , \mathbf{a} , \mathbf{P} \mathbf{P} - \mathbf{D} , \mathbf{a} \mathbf{T} , \mathbf{a}

رار برهم منه فی راه ایر می**را برغ**ران ایر ایر 1. the contract of the mark that the track of the track o t = 1.5, t = 1.5, t = 1.5 (Level of Evidence: C) to a contract the second of th $t_1 = t t_1, \dots, t_{r+1}, \dots,$ $t_{i}^{-1}, t_{i}^{-1}, t_{i+1}^{-1}, t_{i$ (Level of Evidence: C)

B.L., -T. M. a.T. a. a. S., a.a. P. A. d. a.



A ... S.

Ca, Ila

.4. NTG

.4. Ca 🔎 C a_{not} B, 🔻 , . . .

Ca, I (

🗸 . L Mana 🚬 🔏

- Ca. I $(-1 i_{1} i_{1} i_{1} i_{1} + i_{1} + i_{2} + i_{3} i_{1} + i_{4} + i_{5} + i_{1} + i_{4} + i_{5} + i_{1} + i_{2} + i_{3} + i_{4} + i_{5} + i_{5}$
 - $\frac{1}{1} \frac{1}{1} \frac{1}$

 - (Level of Evidence: A).
 - $=\frac{1}{2}\left(\frac{1}{2}\frac{1}{4},\frac{1}{4}\frac{1}{4},\frac{1}{4}\frac{$

. D ab . M .

a /P -D

.S . . . C . a . . a

.W Mara

 \underline{t} . \underline Evidence: B)

 $||\cdot||\cdot||\cdot||_{L^{1}(\mathbb{R}^{3})} + ||t_{1}||^{2} ||t_{1}||^$ $\frac{1}{1} \frac{1}{2} \frac{1}$) (Level of Evidence: B)

Pa lE a la

Ca. I $\frac{1}{3}, \frac{1}{3}, \frac{1}$

∡tla, a a

####